ArticleCancer medicine2026
Prognostic Value and Therapeutic Implications of MRI-Based Negative Lymph Nodes in Nasopharyngeal Carcinoma.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundThis study aimed to evaluate the prognostic significance of negative lymph nodes (LNnegs) identified by magnetic resonance imaging (MRI) and treatment implications in patients with N0 locoregionally advanced NPC.
methodsThis retrospective cohort study included 753 patients with T3-4N0M0 NPC receiving concurrent chemoradiotherapy (CCRT) with or without induction chemotherapy (IC) at two independent hospitals. Pre-treatment and post-radiotherapy MRI scans were performed. Recursive partitioning analysis (RPA) stratified patients by radiological LNneg features. Cox regression and Kaplan-Meier analysis were performed with overall survival (OS) as the primary endpoint.
resultsNeck LNneg levels and the short-axial diameter (SD) of the largest cervical LNneg were identified as significant factors associated with OS through Cox analysis (all p ≤ 0.009). Incorporating these two factors, RPA categorized patients into RPA-I (n = 177; ≥ 4 LNneg levels and SD decreased by > 40%) and RPA-II (n = 576; < 4 LNneg levels, or ≥ 4 levels and SD decreased by ≤ 40%). The 5-year OS in RPA-I was significantly better than in RPA-II (98.3% vs. 89.5%; hazard ratio [HR]: 0.16; 95% confidence interval [CI]: 0.05-0.50; p < 0.001), validated after propensity score matching (n = 177 vs. 177; HR: 0.20; 95% CI: 0.06-0.70; p = 0.005). The OS advantage of RPA-I was significantly influenced by the cumulative cisplatin dose during CCRT (≥ 200 mg/m
conclusionsDispersed LNnegs with a considerable decrease in the SD of the largest cervical LNneg in T3-4N0M0 NPC indicated a low OS risk and potential benefit from a cumulative cisplatin dose of ≥ 200 mg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.